TPP2: A promising drug target and biomarker for treating neurodegenerative diseases

Target Name: TPP2

NCBI ID: G7174

TPP2

TPP2: A promising drug target and biomarker for treating neurodegenerative diseases

Tripeptidyl peptidase 2 (TPPT) is a protein that is expressed in various tissues and cells of the human body. It is a member of the superfamily of intramolecular hydrolases, which are involved in the breaking down various types of peptides. TPPT is one of the most abundant enzymes in the brain and is involved in the processing of the neurotransmitter dopamine. The TPPT gene has four splice variants, two of which have been shown to be expressed in the brain. TPPT has been linked to various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The search for new drug targets and biomarkers has become a major focus in the development of treatments for neurodegenerative diseases. One promising candidate for drug targeting is TPPT. TPPT has been shown to be involved in the production of amyloid peptides, which are thought to contribute to the development of neurodegenerative diseases. By inhibiting TPPT, it may be possible to reduce the production of amyloid peptides and potentially slow the progression of neurodegenerative diseases.

Expression and function of TPPT

TPPT is a 21-kDa protein that is expressed in various tissues and cells of the human body. It is mainly produced in the brain, where it is involved in the processing of dopamine. TPPT has four known splice variants, which have different amino acid sequences. splice variant 1 (TPPT1) is the most abundant and is responsible for most of the protein's functional activity. splice variant 2 (TPPT2) is expressed in the heart and is thought to play a role in cardiac function. splice variant 3 (TPPT3) is expressed in the liver and is involved in the metabolism of drugs. splice variant 4 (TPPT4) is the least abundant and has not been shown to have any significant function.

TPPT is involved in the breaking down of dopamine peptides into smaller peptides, which are then processed into amyloid peptides. These amyloid peptides are thought to contribute to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. TPPT has been shown to be involved in the production of amyloid peptides in both the brain and the liver.

TPPT has been shown to have various functions in the brain, including modulating the levels of dopamine, neurotransmitter release, and neuroinflammation. TPPT has been shown to regulate the levels of dopamine in the brain by breaking down dopamine peptides into smaller peptides. It has also been shown to modulate neurotransmitter release by activating dopamine release and inhibiting neurotransmitter release. TPPT has been shown to play a role in neuroinflammation by regulating the levels of pro-inflammatory cytokines in the brain.

Drug targeting TPPT

TPPT is a promising drug target for treating neurodegenerative diseases. By inhibiting TPPT, it may be possible to reduce the production of amyloid peptides and potentially slow the progression of neurodegenerative diseases. Several studies have shown that inhibiting TPPT can be effective in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

One possible approach to drug targeting TPPT is to use small molecules that inhibit TPPT activity. Several studies have shown that inhibitors of TPPT, such as 1-butyl-3-[(1-methylethenyl)ammonio]-2-propanethiol (BMT), have the potential to slow the progression of neurodegenerative diseases. BMT is a metabolite of the amino acid leucine, which has been shown to have anti-inflammatory properties and to inhibit TPPT activity.

Another possible approach to drug targeting TPPT is to use antibodies that specifically bind to TPPT and inhibit its activity

Protein Name: Tripeptidyl Peptidase 2

Functions: Cytosolic tripeptidyl-peptidase that releases N-terminal tripeptides from polypeptides and is a component of the proteolytic cascade acting downstream of the 26S proteasome in the ubiquitin-proteasome pathway (PubMed:25525876, PubMed:30533531). It plays an important role in intracellular amino acid homeostasis (PubMed:25525876). Stimulates adipogenesis (By similarity)

The "TPP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets